Yesterday, the CFO of SCYNEXIS (SCYX), Francois Eric, bought shares of SCYX for $3,750.
In addition to Francois Eric, 8 other SCYX executives reported Buy trades in the last month. This recent transaction increases Francois Eric’s holding in the company by 5.39% to a total of $77.43K.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.10 and a one-year low of $4.20. Currently, SCYNEXIS has an average volume of 728.51K. SCYX’s market cap is $77.13 million and the company has a P/E ratio of -1.60.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $31.75, reflecting a -78.7% downside. Starting in January 2020, SCYX received 36 Buy ratings in a row. Five different firms, including Ladenburg Thalmann & Co. and Maxim Group, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
